Protalex (PRTX) 10-Q 26 Dec 13 2014 Q2 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	6 Months Ended
	Nov. 30, 2013	Dec. 26, 2013
Document Information [Line Items]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Nov-13	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'
Trading Symbol	'PRTX	'
Entity Common Stock, Shares Outstanding	'	28,296,180
Entity Registrant Name	'PROTALEX INC	'
Entity Central Index Key	'0001099215	'
Current Fiscal Year End Date	'--05-31	'
Entity Filer Category	'Smaller Reporting Company	'

CONDENSED_BALANCE_SHEETS

CONDENSED BALANCE SHEETS (USD $)	Nov. 30, 2013	31-May-13
CURRENT ASSETS:	'	'
Cash and cash equivalents	$1,083,940	$2,457,046
Prepaid expenses	85,436	42,320
Total current assets	1,169,376	2,499,366
OTHER ASSETS:	'	'
Intellectual technology property, net of accumulated amortization of $13,578 and $13,068 as of November 30, 2013 and May 31, 2013, respectively	5,957	6,467
Total other assets	5,957	6,467
Total Assets	1,175,333	2,505,833
CURRENT LIABILITIES:	'	'
Accounts payable	273,818	671,738
Accrued expenses	260,828	62,517
Current portion - long term debt, related party,	0	4,210,833
Total current liabilities	534,646	4,945,088
LONG TERM LIABILITIES:	'	'
Senior Secured Note - related party	9,219,366	6,000,000
Senior Secured Note Accrued Interest - related party	38,414	57,616
Total liabilities	9,792,426	11,002,704
STOCKHOLDERS' EQUITY (DEFICIT)	'	'
Preferred stock, par value $0.00001, 1,000,000 shares authorized; none issued and outstanding	0	0
Common stock, par value $0.00001, 100,000,000 shares authorized; 28,296,180 and 18,926,615 shares issued and outstanding, respectively	283	189
Additional paid in capital	56,121,470	53,237,993
Deficit accumulated during the development stage	-64,738,846	-61,735,053
Total stockholders’ equity (deficit)	-8,617,093	-8,496,871
Total liabilities and stockholders’ equity (deficit)	$1,175,333	$2,505,833

CONDENSED_BALANCE_SHEETS_Paren

CONDENSED BALANCE SHEETS (Parenthetical) (USD $)	Nov. 30, 2013	31-May-13
Intellectual technology property, accumulated amortization	$13,578	$13,068
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	28,296,180	18,926,615
Common stock, shares outstanding	28,296,180	18,926,615

STATEMENTS_OF_OPERATIONS

STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		6 Months Ended		170 Months Ended
	Nov. 30, 2013	Nov. 30, 2012	Nov. 30, 2013	Nov. 30, 2012	Nov. 30, 2013
Revenues	$0	$0	$0	$0	$0
Operating Expenses	'	'	'	'	'
Research and development (including depreciation and amortization)	685,409	835,031	1,618,527	1,510,133	37,994,022
Administrative (including depreciation and amortization)	607,002	243,560	979,761	557,687	20,794,196
Professional fees	130,887	87,978	260,664	213,578	5,332,266
Depreciation and amortization	255	255	510	510	183,476
Operating loss	-1,423,553	-1,166,824	-2,859,462	-2,281,908	-64,303,960
Other income (expense)	'	'	'	'	'
Interest income	1	3	2	27	2,211,849
Interest expense	-67,998	-254,142	-144,333	-503,117	-2,646,735
Net loss	($1,491,550)	($1,420,963)	($3,003,793)	($2,784,998)	($64,738,846)
Weighted average number of common shares outstanding	28,296,180	18,926,615	23,767,557	18,926,615	'
Loss per common share - basic and diluted	($0.05)	($0.08)	($0.13)	($0.15)	'

CONDENSED_STATEMENT_OF_CHANGES

CONDENSED STATEMENT OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT) (USD $)

3 Months Ended

6 Months Ended

9 Months Ended

12 Months Ended

170 Months Ended

Nov. 30, 2013

Nov. 30, 2013

31-May-00

31-May-13

31-May-12

31-May-11

31-May-10

31-May-09

31-May-08

31-May-07

31-May-06

31-May-05

31-May-04

31-May-03

31-May-02

31-May-01

Nov. 30, 2013

August 13, 2001 - Contribution by stockholders

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$143,569

'

'

Record beneficial conversion value attached to senior secured convertible debt

'

'

'

'

'

1,616,667

521,793

'

'

'

'

'

'

'

'

'

'

Warrants exercised

'

'

'

'

'

'

'

'

'

300,374

786,538

'

'

'

'

'

'

February 28, 2005 - reclass par value for reincorporation into DE as of 12/1/04

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

Purchase of common stock from stockholder

'

'

'

'

'

'

'

'

'

'

'

'

-8,333

-91,667

'

'

'

September 17, 1999 - initial issuance of 2,000 shares for intellectual technology license at $.15 per share

'

'

300

'

'

'

'

'

'

'

'

'

'

'

'

'

'

June 1, 2006 - May 31, 2007 - stock options exercised

'

'

'

'

'

'

'

'

'

15,200

'

'

'

'

'

'

'

September 30, 1999 - cost of public shell acquisition over net assets acquired to be accounted for as a Recapitalization

'

'

-250,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

2,155,000

'

'

'

1,037,500

2,000,000

'

'

'

'

'

'

'

1,102,000

425,000

'

September 19, 2003 - repurchase and retired 598,961 shares for $300,000

'

'

'

'

'

'

'

'

'

'

'

'

-300,000

'

'

'

'

November 15, 1999 - reverse merger transaction with Enerdyne Corporation, net transaction amounts

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

May 31, 2004 - reclassify common stock contra to common stock

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

November 26, 2001 - options issued to board member

'

'

'

'

'

'

'

'

'

'

'

'

'

'

133,000

'

'

May 31, 2001 - Forgiveness of debt owed to stockholder

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

40,000

'

Net loss

-1,491,550

-3,003,793

-250,689

-6,280,234

-4,444,584

-3,357,882

-3,067,842

-7,230,206

-10,490,758

-8,451,942

-6,104,402

-5,567,729

-2,989,364

-1,665,090

-1,280,465

-553,866

-64,738,846

Ending balance

-8,617,093

-8,617,093

346,655

-8,496,871

-3,123,614

491,826

1,070,819

1,281,127

7,758,065

17,237,798

9,329,595

8,606,813

8,996,388

243,570

355,893

257,789

-8,617,093

Employee

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share based compensation

'

728,571

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

November 30, 2004 - adjust March 1, 2004 common stock issued to employee

'

'

'

'

'

'

'

'

'

'

'

-20,000

'

'

'

'

'

Board Members, Employees and Consultants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share based compensation

'

'

'

'

'

'

'

753,268

1,011,025

1,826,850

'

'

'

'

'

'

'

Compensation related to stock options issued

'

'

'

'

'

'

'

'

'

'

404,679

308,711

448,096

287,343

'

'

'

Private Placement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

'

'

'

'

'

'

'

14,217,721

'

'

'

'

'

'

'

Employees and Debt Holders

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share based compensation

'

'

'

906,977

829,144

124,722

335,741

'

'

'

'

'

'

'

'

'

'

Issuance During Period 1st

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

25,000

'

'

'

'

'

'

'

'

'

'

1,263,000

'

'

'

Issuance During Period 1st | President

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

'

'

'

'

'

'

'

'

'

'

16,418

'

'

'

'

Issuance During Period 1st | Employee

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

'

'

'

'

'

'

'

'

100,000

38,250

'

'

'

'

'

Issuance During Period 2nd

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

165,400

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance During Period 2nd | President

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

'

'

'

'

'

'

'

'

'

'

'

82,841

'

'

'

Issuance During Period 2nd | Employee

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

'

'

'

'

'

'

'

'

25,000

'

'

'

'

'

'

Issuance During Period 2nd | Private Placement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

'

'

'

'

'

'

'

'

'

4,851,193

11,356,063

'

'

'

'

Issuance During Period 3rd | Legal Service

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

15,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance During Period 3rd | Employee

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

'

'

'

'

'

'

'

'

'

'

'

11,250

'

'

'

Issuance During Period 3rd | Private Placement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

'

'

'

'

'

'

'

'

5,510,967

'

'

'

'

'

'

Issuance During Period 3rd | Terminated Employee

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

'

'

'

'

'

'

'

'

'

'

102,438

'

'

'

'

Issuance During Period 4th

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

640,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance During Period 4th | Employee

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

'

'

'

'

'

'

'

'

'

'

127,500

'

'

'

'

Issuance During Period 5th | Interest Due

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

1,644

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

August 13, 2001 - Contribution by stockholders

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

August 13, 2001 - Contribution by stockholders (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

Record beneficial conversion value attached to senior secured convertible debt

'

'

'

'

'

0

0

'

'

'

'

'

'

'

'

'

'

Warrants exercised (in shares)

'

'

'

'

'

'

'

'

'

26,700

70,320

'

'

'

'

'

'

Warrants exercised

'

'

'

'

'

'

'

'

'

0

1

'

'

'

'

'

'

February 28, 2005 - reclass par value for reincorporation into DE as of 12/1/04

'

'

'

'

'

'

'

'

'

'

'

-14,702,070

'

'

'

'

'

Purchase of common stock from stockholder (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

-2,419

-26,191

'

'

'

Purchase of common stock from stockholder

'

'

'

'

'

'

'

'

'

'

'

'

-8,333

-91,667

'

'

'

September 17, 1999 - initial issuance of 2,000 shares for intellectual technology license at $.15 per share (in shares)

'

'

2,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

September 17, 1999 - initial issuance of 2,000 shares for intellectual technology license at $.15 per share

'

'

300

'

'

'

'

'

'

'

'

'

'

'

'

'

'

June 1, 2006 - May 31, 2007 - stock options exercised (in shares)

'

'

'

'

'

'

'

'

'

1,200

'

'

'

'

'

'

'

June 1, 2006 - May 31, 2007 - stock options exercised

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

September 19, 2003 - repurchase and retired 598,961 shares for $300,000 (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

-598,961

'

'

'

'

September 30, 1999 - cost of public shell acquisition over net assets acquired to be accounted for as a Recapitalization (In Shares)

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

September 30, 1999 - cost of public shell acquisition over net assets acquired to be accounted for as a Recapitalization

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued (in shares)

'

9,369,565

'

'

'

4,510,870

8,695,652

'

'

'

'

'

'

'

176,320

85,000

'

Common stock issued

'

94

'

'

'

45

87

'

'

'

'

'

'

'

1,102,000

425,000

'

September 19, 2003 - repurchase and retired 598,961 shares for $300,000

'

'

'

'

'

'

'

'

'

'

'

'

-300,000

'

'

'

'

November 15, 1999 - reverse merger transaction with Enerdyne Corporation, net transaction amounts (in shares)

'

'

1,794,493

'

'

'

'

'

'

'

'

'

'

'

'

'

'

November 15, 1999 - reverse merger transaction with Enerdyne Corporation, net transaction amounts

'

'

118,547

'

'

'

'

'

'

'

'

'

'

'

'

'

'

May 31, 2004 - reclassify common stock contra to common stock (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

May 31, 2004 - reclassify common stock contra to common stock

'

'

'

'

'

'

'

'

'

'

'

'

-368,547

'

'

'

'

November 26, 2001 - options issued to board member

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

May 31, 2001 - Forgiveness of debt owed to stockholder (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

May 31, 2001 - Forgiveness of debt owed to stockholder

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

Net loss

'

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

'

Ending balance (in shares)

28,296,180

28,296,180

2,036,728

18,926,615

18,926,615

18,926,615

14,415,745

5,720,093

5,720,093

5,720,093

4,477,990

3,878,644

3,356,887

2,449,591

2,298,048

2,121,728

28,296,180

Ending balance

283

283

965,891

189

189

189

144

57

57

57

45

39

14,683,854

3,758,315

2,492,891

1,390,891

283

Common Stock | Employee

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share based compensation (in shares)

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share based compensation

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

November 30, 2004 - adjust March 1, 2004 common stock issued to employee (in shares)

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

November 30, 2004 - adjust March 1, 2004 common stock issued to employee

'

'

'

'

'

'

'

'

'

'

'

-20,000

'

'

'

'

'

Common Stock | Board Members, Employees and Consultants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share based compensation (in shares)

'

'

'

'

'

'

'

0

0

0

'

'

'

'

'

'

'

Share based compensation

'

'

'

'

'

'

'

0

0

0

'

'

'

'

'

'

'

Compensation related to stock options issued

'

'

'

'

'

'

'

'

'

'

0

0

0

0

'

'

'

Common Stock | Private Placement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued (in shares)

'

'

'

'

'

'

'

'

'

1,214,203

'

'

'

'

'

'

'

Common stock issued

'

'

'

'

'

'

'

'

'

12

'

'

'

'

'

'

'

Common Stock | Employees and Debt Holders

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share based compensation (in shares)

'

'

'

0

0

0

0

'

'

'

'

'

'

'

'

'

'

Share based compensation

'

'

'

0

0

0

0

'

'

'

'

'

'

'

'

'

'

Common Stock | Issuance During Period 1st

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued (in shares)

'

'

17

'

'

'

'

'

'

'

'

'

'

168,400

'

'

'

Common stock issued

'

'

25,000

'

'

'

'

'

'

'

'

'

'

1,263,000

'

'

'

Common Stock | Issuance During Period 1st | President

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

1,667

'

'

'

'

Common stock issued

'

'

'

'

'

'

'

'

'

'

'

'

16,418

'

'

'

'

Common Stock | Issuance During Period 1st | Employee

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued (in shares)

'

'

'

'

'

'

'

'

'

'

8,000

3,000

'

'

'

'

'

Common stock issued

'

'

'

'

'

'

'

'

'

'

0

38,250

'

'

'

'

'

Common Stock | Issuance During Period 2nd

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued (in shares)

'

'

91,889

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

165,400

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock | Issuance During Period 2nd | President

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

8,334

'

'

'

Common stock issued

'

'

'

'

'

'

'

'

'

'

'

'

'

82,841

'

'

'

Common Stock | Issuance During Period 2nd | Employee

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued (in shares)

'

'

'

'

'

'

'

'

'

'

2,000

'

'

'

'

'

'

Common stock issued

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

Common Stock | Issuance During Period 2nd | Private Placement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued (in shares)

'

'

'

'

'

'

'

'

'

'

'

518,757

1,489,129

'

'

'

'

Common stock issued

'

'

'

'

'

'

'

'

'

'

'

5

11,356,063

'

'

'

'

Common Stock | Issuance During Period 3rd | Legal Service

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued (in shares)

'

'

20,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

15,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock | Issuance During Period 3rd | Employee

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

1,000

'

'

'

Common stock issued

'

'

'

'

'

'

'

'

'

'

'

'

'

11,250

'

'

'

Common Stock | Issuance During Period 3rd | Private Placement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued (in shares)

'

'

'

'

'

'

'

'

'

'

519,026

'

'

'

'

'

'

Common stock issued

'

'

'

'

'

'

'

'

'

'

5

'

'

'

'

'

'

Common Stock | Issuance During Period 3rd | Terminated Employee

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

7,880

'

'

'

'

Common stock issued

'

'

'

'

'

'

'

'

'

'

'

'

102,438

'

'

'

'

Common Stock | Issuance During Period 4th

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued (in shares)

'

'

128,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

640,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock | Issuance During Period 4th | Employee

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

10,000

'

'

'

'

Common stock issued

'

'

'

'

'

'

'

'

'

'

'

'

127,500

'

'

'

'

Common Stock | Issuance During Period 5th | Interest Due

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued (in shares)

'

'

329

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

1,644

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Additional Paid in Capital

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

August 13, 2001 - Contribution by stockholders

'

'

'

'

'

'

'

'

'

'

'

'

'

'

143,569

'

'

Record beneficial conversion value attached to senior secured convertible debt

'

'

'

'

'

1,616,667

521,793

'

'

'

'

'

'

'

'

'

'

Warrants exercised

'

'

'

'

'

'

'

'

'

300,374

786,537

'

'

'

'

'

'

February 28, 2005 - reclass par value for reincorporation into DE as of 12/1/04

'

'

'

'

'

'

'

'

'

'

'

14,702,070

'

'

'

'

'

Purchase of common stock from stockholder

'

'

'

'

'

'

'

'

'

'

'

'

0

0

'

'

'

September 17, 1999 - initial issuance of 2,000 shares for intellectual technology license at $.15 per share

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

June 1, 2006 - May 31, 2007 - stock options exercised

'

'

'

'

'

'

'

'

'

15,200

'

'

'

'

'

'

'

September 30, 1999 - cost of public shell acquisition over net assets acquired to be accounted for as a Recapitalization

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

2,154,906

'

'

'

1,037,455

1,999,913

'

'

'

'

'

'

'

0

0

'

September 19, 2003 - repurchase and retired 598,961 shares for $300,000

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

November 15, 1999 - reverse merger transaction with Enerdyne Corporation, net transaction amounts

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

May 31, 2004 - reclassify common stock contra to common stock

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

November 26, 2001 - options issued to board member

'

'

'

'

'

'

'

'

'

'

'

'

'

'

133,000

'

'

May 31, 2001 - Forgiveness of debt owed to stockholder

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

40,000

'

Net loss

'

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

'

Ending balance

56,121,470

56,121,470

0

53,237,993

52,331,016

51,501,872

48,723,028

45,865,581

45,112,313

44,101,288

27,741,155

20,913,977

1,052,008

603,912

316,569

40,000

56,121,470

Additional Paid in Capital | Employee

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share based compensation

'

728,571

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

November 30, 2004 - adjust March 1, 2004 common stock issued to employee

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

Additional Paid in Capital | Board Members, Employees and Consultants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share based compensation

'

'

'

'

'

'

'

753,268

1,011,025

1,826,850

'

'

'

'

'

'

'

Compensation related to stock options issued

'

'

'

'

'

'

'

'

'

'

404,679

308,711

448,096

287,343

'

'

'

Additional Paid in Capital | Private Placement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

'

'

'

'

'

'

'

14,217,709

'

'

'

'

'

'

'

Additional Paid in Capital | Employees and Debt Holders

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share based compensation

'

'

'

906,977

829,144

124,722

335,741

'

'

'

'

'

'

'

'

'

'

Additional Paid in Capital | Issuance During Period 1st

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

0

'

'

'

'

'

'

'

'

'

'

0

'

'

'

Additional Paid in Capital | Issuance During Period 1st | President

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

Additional Paid in Capital | Issuance During Period 1st | Employee

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

'

'

'

'

'

'

'

'

100,000

0

'

'

'

'

'

Additional Paid in Capital | Issuance During Period 2nd

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Additional Paid in Capital | Issuance During Period 2nd | President

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

Additional Paid in Capital | Issuance During Period 2nd | Employee

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

'

'

'

'

'

'

'

'

25,000

'

'

'

'

'

'

Additional Paid in Capital | Issuance During Period 2nd | Private Placement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

'

'

'

'

'

'

'

'

'

4,851,188

0

'

'

'

'

Additional Paid in Capital | Issuance During Period 3rd | Legal Service

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Additional Paid in Capital | Issuance During Period 3rd | Employee

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

Additional Paid in Capital | Issuance During Period 3rd | Private Placement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

'

'

'

'

'

'

'

'

5,510,962

'

'

'

'

'

'

Additional Paid in Capital | Issuance During Period 3rd | Terminated Employee

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

Additional Paid in Capital | Issuance During Period 4th

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Additional Paid in Capital | Issuance During Period 4th | Employee

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

Additional Paid in Capital | Issuance During Period 5th | Interest Due

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock- Contra

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

August 13, 2001 - Contribution by stockholders

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

Record beneficial conversion value attached to senior secured convertible debt

'

'

'

'

'

0

0

'

'

'

'

'

'

'

'

'

'

Warrants exercised

'

'

'

'

'

'

'

'

'

0

0

'

'

'

'

'

'

February 28, 2005 - reclass par value for reincorporation into DE as of 12/1/04

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

Purchase of common stock from stockholder

'

'

'

'

'

'

'

'

'

'

'

'

0

0

'

'

'

September 17, 1999 - initial issuance of 2,000 shares for intellectual technology license at $.15 per share

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

June 1, 2006 - May 31, 2007 - stock options exercised

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

September 30, 1999 - cost of public shell acquisition over net assets acquired to be accounted for as a Recapitalization

'

'

-250,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

0

'

'

'

0

0

'

'

'

'

'

'

'

0

0

'

September 19, 2003 - repurchase and retired 598,961 shares for $300,000

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

November 15, 1999 - reverse merger transaction with Enerdyne Corporation, net transaction amounts

'

'

-118,547

'

'

'

'

'

'

'

'

'

'

'

'

'

'

May 31, 2004 - reclassify common stock contra to common stock

'

'

'

'

'

'

'

'

'

'

'

'

368,547

'

'

'

'

November 26, 2001 - options issued to board member

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

May 31, 2001 - Forgiveness of debt owed to stockholder

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

Net loss

'

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

'

Ending balance

0

0

-368,547

0

0

0

0

0

0

0

0

0

0

-368,547

-368,547

-368,547

0

Common Stock- Contra | Employee

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share based compensation

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

November 30, 2004 - adjust March 1, 2004 common stock issued to employee

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

Common Stock- Contra | Board Members, Employees and Consultants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share based compensation

'

'

'

'

'

'

'

0

0

0

'

'

'

'

'

'

'

Compensation related to stock options issued

'

'

'

'

'

'

'

'

'

'

0

0

0

0

'

'

'

Common Stock- Contra | Private Placement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

Common Stock- Contra | Employees and Debt Holders

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share based compensation

'

'

'

0

0

0

0

'

'

'

'

'

'

'

'

'

'

Common Stock- Contra | Issuance During Period 1st

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

0

'

'

'

'

'

'

'

'

'

'

0

'

'

'

Common Stock- Contra | Issuance During Period 1st | President

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

Common Stock- Contra | Issuance During Period 1st | Employee

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

'

'

'

'

'

'

'

'

0

0

'

'

'

'

'

Common Stock- Contra | Issuance During Period 2nd

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock- Contra | Issuance During Period 2nd | President

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

Common Stock- Contra | Issuance During Period 2nd | Employee

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

Common Stock- Contra | Issuance During Period 2nd | Private Placement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

'

'

'

'

'

'

'

'

'

0

0

'

'

'

'

Common Stock- Contra | Issuance During Period 3rd | Legal Service

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock- Contra | Issuance During Period 3rd | Employee

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

Common Stock- Contra | Issuance During Period 3rd | Private Placement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

Common Stock- Contra | Issuance During Period 3rd | Terminated Employee

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

Common Stock- Contra | Issuance During Period 4th

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock- Contra | Issuance During Period 4th | Employee

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

Common Stock- Contra | Issuance During Period 5th | Interest Due

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deficit Accumulated During The Development Stage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

August 13, 2001 - Contribution by stockholders

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

Record beneficial conversion value attached to senior secured convertible debt

'

'

'

'

'

0

0

'

'

'

'

'

'

'

'

'

'

Warrants exercised

'

'

'

'

'

'

'

'

'

0

0

'

'

'

'

'

'

February 28, 2005 - reclass par value for reincorporation into DE as of 12/1/04

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

Purchase of common stock from stockholder

'

'

'

'

'

'

'

'

'

'

'

'

0

0

'

'

'

September 17, 1999 - initial issuance of 2,000 shares for intellectual technology license at $.15 per share

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

June 1, 2006 - May 31, 2007 - stock options exercised

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

September 30, 1999 - cost of public shell acquisition over net assets acquired to be accounted for as a Recapitalization

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

0

'

'

'

0

0

'

'

'

'

'

'

'

0

0

'

September 19, 2003 - repurchase and retired 598,961 shares for $300,000

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

November 15, 1999 - reverse merger transaction with Enerdyne Corporation, net transaction amounts

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

May 31, 2004 - reclassify common stock contra to common stock

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

November 26, 2001 - options issued to board member

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

May 31, 2001 - Forgiveness of debt owed to stockholder

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

Net loss

'

-3,003,793

-250,689

-6,280,234

-4,444,584

-3,357,882

-3,067,842

-7,230,206

-10,490,758

-8,451,942

-6,104,402

-5,567,729

-2,989,364

-1,665,090

-1,280,465

-553,866

'

Ending balance

-64,738,846

-64,738,846

-250,689

-61,735,053

-55,454,819

-51,010,235

-47,652,353

-44,584,511

-37,354,305

-26,863,547

-18,411,605

-12,307,203

-6,739,474

-3,750,110

-2,085,020

-804,555

-64,738,846

Deficit Accumulated During The Development Stage | Employee

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share based compensation

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

November 30, 2004 - adjust March 1, 2004 common stock issued to employee

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

Deficit Accumulated During The Development Stage | Board Members, Employees and Consultants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share based compensation

'

'

'

'

'

'

'

0

0

0

'

'

'

'

'

'

'

Compensation related to stock options issued

'

'

'

'

'

'

'

'

'

'

0

0

0

0

'

'

'

Deficit Accumulated During The Development Stage | Private Placement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

Deficit Accumulated During The Development Stage | Employees and Debt Holders

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share based compensation

'

'

'

0

0

0

0

'

'

'

'

'

'

'

'

'

'

Deficit Accumulated During The Development Stage | Issuance During Period 1st

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

0

'

'

'

'

'

'

'

'

'

'

0

'

'

'

Deficit Accumulated During The Development Stage | Issuance During Period 1st | President

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

Deficit Accumulated During The Development Stage | Issuance During Period 1st | Employee

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

'

'

'

'

'

'

'

'

0

0

'

'

'

'

'

Deficit Accumulated During The Development Stage | Issuance During Period 2nd

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deficit Accumulated During The Development Stage | Issuance During Period 2nd | President

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

Deficit Accumulated During The Development Stage | Issuance During Period 2nd | Employee

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

Deficit Accumulated During The Development Stage | Issuance During Period 2nd | Private Placement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

'

'

'

'

'

'

'

'

'

0

0

'

'

'

'

Deficit Accumulated During The Development Stage | Issuance During Period 3rd | Legal Service

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deficit Accumulated During The Development Stage | Issuance During Period 3rd | Employee

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

Deficit Accumulated During The Development Stage | Issuance During Period 3rd | Private Placement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

Deficit Accumulated During The Development Stage | Issuance During Period 3rd | Terminated Employee

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

Deficit Accumulated During The Development Stage | Issuance During Period 4th

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deficit Accumulated During The Development Stage | Issuance During Period 4th | Employee

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

Deficit Accumulated During The Development Stage | Issuance During Period 5th | Interest Due

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

$0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

CONDENSED_STATEMENT_OF_CHANGES1

CONDENSED STATEMENT OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT) (Parenthetical) (USD $)

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

31-May-00

31-May-11

31-May-10

31-May-04

31-May-03

31-May-02

31-May-01

31-May-00

31-May-03

31-May-00

31-May-00

31-May-00

31-May-00

31-May-04

31-May-05

31-May-03

31-May-06

31-May-05

31-May-06

31-May-03

31-May-04

31-May-07

31-May-04

31-May-06

31-May-04

Issuance During Period 1st

Issuance During Period 1st

Issuance During Period 2nd

Issuance During Period 4th

Legal Service

Interest Due

President

President

President

Employee

Employee

Employee

Employee

Employee

Private Placement

Private Placement

Private Placement

Terminated Employee

Issuance During Period 3rd

Issuance During Period 5th

Issuance During Period 1st

Issuance During Period 2nd

Issuance During Period 2nd

Issuance During Period 1st

Issuance During Period 1st

Issuance During Period 2nd

Issuance During Period 3rd

Issuance During Period 4th

Issuance During Period 2nd

Issuance During Period 3rd

Issuance During Period 3rd

Common Stock issued, per share

$0.15

'

$0.23

'

'

$6.25

$5

'

$7.50

$1.80

$5

'

'

'

$9.75

'

'

$12.75

'

'

$12.75

$12.50

$8.50

$11.25

$13

Common Stock issued, issuance start date

'

'

'

'

'

'

'

'

'

18-Nov-99

1-May-00

'

'

'

'

15-Jan-03

'

'

'

'

'

'

'

'

'

Common Stock issued, issuance date

17-Sep-99

11-Feb-11

11-Nov-09

'

'

7-Nov-01

7-Dec-00

27-Oct-99

5-Jul-02

'

'

1-Jan-00

27-May-00

15-Jun-03

25-May-05

'

23-Aug-05

13-Jan-05

19-Oct-05

14-May-03

1-Mar-04

7-Jul-06

18-Sep-03

30-Dec-05

12-Dec-03

Common Stock issued, issuance end date

'

'

'

'

'

'

'

'

'

7-Feb-00

27-May-00

'

'

'

'

15-May-03

'

'

'

'

'

'

'

'

'

Common stock shares repurchased, per share

'

'

'

'

$3.50

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock shares repurchased, start date

'

'

'

'

1-Jul-02

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock shares repurchased, end date

'

'

'

'

1-May-03

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock shares repurchased, date

'

'

'

15-Jun-03

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock shares repurchased and retired, date

'

'

'

19-Sep-03

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

CONDENSED_STATEMENTS_OF_CASH_F

CONDENSED STATEMENTS OF CASH FLOWS (USD $)	6 Months Ended		170 Months Ended
	Nov. 30, 2013	Nov. 30, 2012	Nov. 30, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:	'	'	'
Net loss	($3,003,793)	($2,784,998)	($64,738,846)
Adjustments to reconcile net loss to net cash and cash equivalents used in operating activities	'	'	'
(Gain) on disposal of equipment, net	0	0	-81,544
Depreciation and amortization	510	468,460	1,971,650
Equity based expense	728,571	342,312	9,322,542
(Increase)/decrease in:	'	'	'
Prepaid expenses and deposits	-43,116	-42,894	-93,426
Increase/(decrease) in:	'	'	'
Accounts payable and accrued expenses	-55,278	59,136	1,352,930
Net cash and cash equivalents used in operating activities	-2,373,106	-1,957,984	-52,266,694
CASH FLOWS FROM INVESTING ACTIVITIES:	'	'	'
Acquisition of intellectual technology license - fee portion	0	0	-20,000
Refund of security deposits	0	0	7,990
Acquisition of equipment	0	0	-905,936
Excess of amounts paid for public shell over assets acquired to be accounted for as a recapitalization	0	0	-250,000
Proceeds from disposal of equipment	0	0	229,135
Net cash and cash equivalents used in investing activities	0	0	-938,811
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'	'
Proceeds from stock issuance, including options and warrants exercised	0	0	42,658,458
Principal payment on equipment notes payable and capital leases	0	0	-295,411
Contribution by stockholders	0	0	183,569
Principal payment on note payable to individuals	0	0	-225,717
Issuance of note payable to individuals	1,000,000	1,800,000	12,368,546
Acquisition of common stock	0	0	-400,000
Net cash and cash equivalents provided by financing activities	1,000,000	1,800,000	54,289,445
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	-1,373,106	-157,984	1,083,940
Cash and cash equivalents, beginning of period	2,457,046	190,395	0
Cash and cash equivalents, ending of period	1,083,940	32,411	1,083,940
SUPPLEMENTAL SCHEDULE OF CASH FLOW INFORMATION:	'	'	'
Interest paid	0	0	66,770
Taxes paid	0	0	100
NON-CASH FINANCING ACTIVITIES:	'	'	'
Conversion of debt for equity	$2,155,000	$0	$3,192,500

ORGANIZATION_AND_BUSINESS_ACTI

ORGANIZATION AND BUSINESS ACTIVITIES	6 Months Ended
	Nov. 30, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
ORGANIZATION AND BUSINESS ACTIVITIES	'
	NOTE 1. ORGANIZATION AND BUSINESS ACTIVITIES
	Protalex, Inc., a Delaware corporation, (“we,” “us,” “our,” the “Company” or “its”) is a development stage company focused on the development of a class of biopharmaceutical drugs for treating autoimmune inflammatory diseases including rheumatoid arthritis (RA).  Its lead product, PRTX-100, is a formulation of highly-purified staphylococcal protein A, which is an immunomodulatory protein produced by bacteria.
	The Company maintains an administrative office in Summit, New Jersey and currently outsources all of its product development and regulatory activities, including clinical trial activities, manufacturing and laboratory operations to third-party contract research organizations and facilities.
	In April 2009, the Company ceased all operations and terminated all employees in light of insufficient funds to continue its clinical trials and related product development.  The Company’s business was dormant until new management took control of its operations in November 2009 following the change in control transaction more fully described below.  The Company is currently actively pursuing the commercial development of PRTX-100 for the treatment of RA.
	On December 8, 2010, the Company effected a reverse stock split of the outstanding shares of its common stock, with par value of $0.00001 per share (“Common Stock”), on the basis of one share of Common Stock for each five shares of Common Stock outstanding.  Unless otherwise noted, all references in these financial statements and notes to financial statements to number of shares, price per share and weighted average number of shares outstanding of Common Stock prior to this reverse stock split have been adjusted to reflect the reverse stock split on a retroactive basis.
	PRTX-100 has demonstrated effectiveness in animal models of autoimmune diseases as well as demonstrated activity on cultured human immune cells at very low concentrations; however, the effectiveness of PRTX-100 shown in pre-clinical studies using animal models may not be predictive of the results that the Company would see in future human clinical trials.  The safety, tolerability and pharmacokinetics (PK) of PTRX-100 in humans have now been characterized in four clinical studies, with a fifth clinical study nearing completion.  The Company does not anticipate generating operating revenue for the foreseeable future and does not currently have any products that are marketable.

CHANGE_OF_OWNERSHIP_TRANSACTIO

CHANGE OF OWNERSHIP TRANSACTION	6 Months Ended
	Nov. 30, 2013
Working Capital Information [Abstract]	'
CHANGE OF OWNERSHIP TRANSACTION	'
	NOTE 2. CHANGE OF OWNERSHIP TRANSACTION
	On November 11, 2009 (the “Effective Date”), the Company consummated a financing transaction (the “Financing”) in which it raised $3,000,000 of working capital pursuant to a Securities Purchase Agreement (the “Purchase Agreement”) with Niobe Ventures, LLC, a Delaware limited liability company (“Niobe”).  Pursuant to the Purchase Agreement, the Company issued to Niobe (i) 8,695,652 restricted shares of Common Stock at a purchase price of $0.23 per share (or $2 million in the aggregate) and (ii) a senior secured convertible promissory note in the principal amount of $1 million convertible into shares of Common Stock at an initial conversion price equal to $0.23 per share (the “$1 Million Secured Note”).  On February 11, 2011, Niobe converted the $1 Million Secured Note, including $37,500 of accrued interest thereon, into 4,510,870 shares of Common Stock.
	On February 11, 2011, for the purpose of providing the Company with additional working capital, pursuant to an existing Credit Facility Agreement dated as of December 2, 2009 (the “Facility”) with Niobe, the Company issued to Niobe a senior secured convertible promissory note in the principal amount of $2 million (the “$2 Million Secured Convertible Note”).  The $2 Million Secured Convertible Note provided for conversion of interest and principal into shares of Common Stock at a conversion price of $0.23 per share, bore interest at a rate of 3% per annum and had a maturity date of December 31, 2012 (which in December 2012 Niobe agreed, for no consideration, to extend until December 31, 2013).
	The $2 Million Secured Convertible Note was convertible into shares of Common Stock at any time, by the holder, subject only to the requirement that the Company have sufficient authorized shares of Common Stock available after taking into account all outstanding shares of Common Stock and the maximum number of shares issuable under all issued and outstanding convertible securities.  On August 27, 2013, Niobe elected to convert the $2 Million Secured Convertible Note and $155,000 of accrued interest thereunder into 9,369,565 shares of Common Stock.
	On February 1, 2012, the Company raised $1,000,000 of working capital pursuant to a loan from Niobe.  The Company issued to Niobe a secured promissory note in the principal amount of $1,000,000 (the “February 2012 Secured Note”).  The February 2012 Secured Note bears interest at a rate of 3% per annum and matures on February 1, 2014.
	On June 5, 2012, the Company raised $1,000,000 of additional working capital pursuant to an incremental loan from Niobe and issued to Niobe a secured promissory note in the principal amount of $1,000,000, which bears interest at a rate of 3% per annum and matures on May 31, 2014 (the “June 2012 Secured Note”).
	On October 1, 2012, the Company raised $800,000 of additional working capital pursuant to an incremental loan from Niobe and issued to Niobe a secured promissory note in the principal amount of $800,000, which bear interest at a rate of 3% per annum and matures on October 1, 2014 (the “October 2012 Secured Note”).
	On December 3, 2012, the Company raised $700,000 of additional working capital pursuant to an incremental loan from Niobe and issued to Niobe a secured promissory note in the principal amount of $700,000, which bears interest at a rate of 3% per annum and matures on October 1, 2014 (the “December 2012 Secured Note”).
	Collectively, the February 2012 Secured Note, the June 2012 Secured Note, the October 2012 Secured Note and the December 2012 Secured Note are hereinafter referred to as the “2012 Secured Notes.”
	On January 18, 2013, the Company raised $2,500,000 of additional working capital pursuant to an incremental loan from Niobe and issued to Niobe a secured promissory note in the principal amount of $2,500,000, which bears interest at a rate of 3% per annum and matures on January 15, 2015 (the “January 2013 Secured Note”).
	On May 13, 2013, the Company raised $2,000,000 of additional working capital pursuant to an incremental loan from Niobe and issued to Niobe a secured promissory note in the principal amount of $2,000,000, which bears interest at a rate of 3% per annum and matures on May 13, 2015 (the “May 2013 Secured Note”).
	On August 27, 2013, the Company raised $1,000,000 of additional working capital pursuant to an incremental loan from Niobe and issued to Niobe a secured promissory note in the principal amount of $1,000,000, which bears interest at a rate of 3% per annum and matures on August 27, 2015 (the “August 2013 Secured Note”).
	Collectively, the January 2013 Secured Note, the May 2013 Secured Note and the August 2013 Secured Note are hereinafter referred to as the “2013 Secured Notes.”
	Collectively, the 2012 Secured Notes and the 2013 Secured Notes represent a total of $9,000,000 in principal amount of loans from Niobe and are hereinafter referred to as the “Secured Notes.”
	On October 11, 2013, the Company issued a Consolidated, Amended and Restated Promissory Note to Niobe in the principal amount of $9,219,366.67 (the “Consolidated Note”).  The face amount of the Consolidated Note reflects the $9,000,000 aggregate principal amount of the Secured Notes plus interest accrued at 3% per annum on each note from its respective date of issuance.  The terms of the Consolidated Note are identical to the Secured Notes except that: (a) the maturity date is September 1, 2015, which is after the latest maturity date of any of the Secured Notes; and (b) it provides for partial mandatory repayment in the event that the Company receives aggregate gross proceeds in excess of $7,500,000 from a single or multiple “Liquidity Events” in an amount equal to twenty-five (25%) percent of such gross proceeds.  A “Liquidity Event” means (a) the sale of any of our equity, or equity-linked, securities, and (b) the receipt of proceeds, directly or indirectly related to a development and/or commercialization relationship entered into with an unaffiliated third party.  In the Secured Notes, the entire principal amount of each note was due, at Niobe’s election, upon the consummation of an equity financing of $7,500,000 or greater.  Consistent with the terms of the Secured Notes and related security agreements entered into, the Company’s obligations under the Consolidated Note are secured by a first priority perfected security interest in all of the assets of the Company pursuant to a Consolidated, Amended and Restated Security Agreement dated October 11, 2013 between the Company and Niobe.
	All of the securities issued in the aforementioned financings were issued in reliance upon the exemption from the registration requirements of the Securities Act of 1933, as amended (the “Act”) pursuant to Section 4(6) and Rule 506 of Regulation D thereof.  The offer, sale and issuance of such securities were made without general solicitation or advertising.  The securities were offered and issued only to “accredited investors” as such term is defined in Rule 501 under the Act.

GOING_CONCERN

GOING CONCERN	6 Months Ended
	Nov. 30, 2013
Going Concern Disclosure [Abstract]	'
GOING CONCERN	'
	NOTE 3. GOING CONCERN
	The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern. The ability of the Company to continue as a going concern is dependent upon developing products that are regulatory approved and market accepted. There is no assurance that these plans will be realized in whole or in part. The financial statements do not include any adjustments that might result from the outcome of these uncertainties.
	Since inception, the Company has incurred an accumulated deficit of $64,738,846 through November 30, 2013. For the years ended May 31, 2013 and 2012, the Company had net losses of $6,280,234 and $4,444,584, respectively and for the six months ended November 30, 2013, the Company had a net loss of $3,003,793.  The Company used $4,733,349 and $2,351,630 of cash in operating activities for the years ended May 31, 2013 and 2012, respectively, and $2,373,106 during the six months ended November 30, 2013.  As of November 30, 2013, the Company had cash and cash equivalents of $1,083,940 and net working capital of $634,730.  The Company has incurred negative cash flow from operating activities since its inception.   The Company has spent, and subject to obtaining additional financing, expects to continue to spend, substantial amounts in connection with executing its business strategy, including continued development efforts relating to PRTX-100.
	The Company has no significant payments due on long-term obligations since, as discussed above in Note 2, on October 11, 2013, the Company issued the Consolidated Note to Niobe.  However, the Company has entered into a significant number of contracts to perform clinical trials during the remainder of 2013 and the early part of 2014 and it will need to raise additional capital in the future to fund the ongoing FDA approval process. If the Company is unable to (a) raise additional capital, (b) obtain approval of its future IND applications, or (c) otherwise achieve successes  in the FDA approval process, its ability to sustain its operations would be significantly jeopardized.
	The most likely sources of additional financing include the private sale of the Company’s equity or debt securities or loans from the Company’s majority stockholder. Additional capital that is required by the Company may not be available on reasonable terms, or at all.

BASIS_OF_PRESENTATION_AND_SUMM

BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Nov. 30, 2013
Accounting Policies [Abstract]	'
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	'
	NOTE 4. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	The interim financial data contained in this Report is unaudited; however in the opinion of management, the interim data includes all adjustments, consisting of normal recurring adjustments, necessary for a fair statement of the results for the interim period. The financial statements included herein have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to such rules and regulations, although the Company believes that the disclosures included herein are adequate to make the information presented not misleading.  The results of operations in interim periods are not necessarily indicative of the results that may be expected for the full year.
	Information regarding the organization and business of the Company, accounting policies followed by the Company and other important information is contained in the notes to the Company's financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended May 31, 2013. This quarterly report should be read in conjunction with such annual report.
	Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions affecting the reported amounts of assets, liabilities, revenues and expense, and the disclosure of contingent assets and liabilities. Estimated amounts could differ materially from actual results.
	Loss Per Common Share
	The Financial Accounting Standards Board (FASB) has issued guidance for “Earnings Per Share” which provides for the calculation of “Basic” and “Diluted” earnings per share. Basic earnings per share includes no dilution and is computed by dividing net loss to common stockholders by the weighted average number of common shares outstanding for the period. All potentially dilutive securities consisting of employee stock options and warrants have been excluded from the computations since they would be antidilutive. However, these dilutive securities could potentially dilute earnings per share in future periods. As of November 30, 2013 the Company had potentially dilutive securities consisting of 3,117,543 stock options.  As of November 30, 2012, the Company had potentially dilutive securities consisting of 2,642,191 stock options.
	Cash and Cash Equivalents
	For the purposes of reporting cash flows, the Company considers all cash accounts which are not subject to withdrawal restrictions or penalties, and highly liquid investments with original maturities of 60 days or less to be cash and cash equivalents. The cash and cash equivalent deposits are not insured by The Federal Deposit Insurance Corporation.
	Share Based Compensation
	Effective June 1, 2006, the Company adopted the FASB accounting guidance for fair value recognition provisions of the “Accounting for Share-Based Payment” using the modified prospective method.  This standard requires the Company to measure the cost of employee services received in exchange for equity share options granted based on the grant-date fair value of the options.  The cost is recognized as compensation expense over the vesting period of the options.  Under the modified prospective method $728,571 and $342,312 compensation cost is included in operating expenses for the six months ended November 30, 2013 and November 30, 2012, respectively.  These amounts included both the compensation cost of stock options granted prior to but not yet vested as of June 1, 2006 and compensation cost for all options granted subsequent to May 31, 2006.  In accordance with the modified prospective application transition method, prior period results are not restated.  Incremental compensation cost for a modification of the terms or conditions of an award is measured by comparing the fair value of the modified award with the fair value of the award immediately before the modification.  No tax benefit was recorded as of November 30, 2013 in connection with these compensation costs due to the uncertainty regarding ultimate realization of certain net operating loss carryforwards.  The Company has also implemented the SEC interpretations in Staff Accounting Bulletin (“SAB”) for “Share-Based Payments,” in connection with the adoption of FASB accounting guidance.
	The Board of Directors adopted and the stockholders approved the 2003 Stock Option Plan in October 2003 which was subsequently amended in October 2005. The plan was adopted to recognize the contributions made by the Company’s employees, officers, consultants, and directors, to provide those individuals with additional incentive to devote themselves to the Company’s future success, and to improve the Company’s ability to attract, retain and motivate individuals upon whom the Company’s growth and financial success depends. Under the plan, stock options for up to 900,000 shares may be granted as approved by the Board of Directors or the Compensation Committee.  No options granted under the plan are exercisable after the expiration of ten years (or less in the discretion of the Board of Directors or the Compensation Committee) from the date of the grant. The plan will continue in effect until terminated or amended by the Board of Directors.
	The accounting guidance requires the use of a valuation model to calculate the fair value of each stock-based award. The Company uses the Black-Scholes model to estimate the fair value of stock options granted based on the following assumptions:
	Expected Term or Life. The expected term or life of stock options granted issued represents the expected weighted average period of time from the date of grant to the estimated date that the stock option would be fully exercised. The weighted average expected option term was determined using a combination of the “simplified method” for plain vanilla options as allowed by the accounting guidance. The “simplified method” calculates the expected term as the average of the vesting term and original contractual term of the options.
	Expected Volatility. Expected volatility is a measure of the amount by which the Company’s stock price is expected to fluctuate. Expected volatility is based on the historical daily volatility of the price of our common shares. The Company estimated the expected volatility of the stock options at grant date.
	Risk-Free Interest Rate. The risk-free interest rate is based on the implied yield on U.S. Treasury zero-coupon issues with remaining terms equivalent to the expected term of our stock-based awards.
	As of November 30, 2013, there were 3,117,543 stock options outstanding of which an aggregate of 37,000 were options granted under the plan and 3,080,543 were non-plan option grants.  At November 30, 2013, the aggregate unrecognized compensation cost of unvested options, as determined using a Black-Scholes option valuation model, was approximately $376,750 (net of estimated forfeitures) which will be recognized ratably through May 2014.  The remaining amount of options will be valued once they vest upon the future events.  During the six months ended November 30, 2013, the Company granted 100,000 stock options and 40,000 options expired.
	The fair value of the options is estimated on the date of the grant using the Black-Scholes option pricing model with the following assumptions:
		Six Months Ended			Six Months Ended			From Inception
		November 30, 2013			November 30, 2012			Through
								November 30, 2013
	Dividends per year		0			0			0
	Volatility percentage		418% - 426	%		97.5	%		90%-426	%
	Risk free interest rate		2.13	%		3.47	%		1.74%-5.11	%
	Expected life (years)		7.0-10.0			7.0-10.0			10-Mar
	Weighted Average Fair Value	$	1.24		$	1.07		$	2.3

RECENT_ACCOUNTING_PRONOUNCEMEN

RECENT ACCOUNTING PRONOUNCEMENTS	6 Months Ended
	Nov. 30, 2013
Accounting Changes and Error Corrections [Abstract]	'
RECENT ACCOUNTING PRONOUNCEMENTS	'
	NOTE 5. RECENT ACCOUNTING PRONOUNCEMENTS
	Management does not believe that any recently issued, but not yet effective, accounting standards could have a material effect on the accompanying consolidated financial statements.  As new accounting pronouncements are issued, the Company will adopt those that are applicable under the circumstances.

RELATED_PARTIES

RELATED PARTIES	6 Months Ended
	Nov. 30, 2013
Related Party Transactions [Abstract]	'
RELATED PARTIES	'
	NOTE 6. RELATED PARTIES
	Niobe, the majority stockholder of the Company and the holder of the Consolidated Note (defined in Note 2, above), is controlled by Arnold P. Kling, the Company’s president and director.
	During the year ended May 31, 2013, the Company issued an aggregate of 350,000 options to Kirk M. Warshaw, the Company’s chief financial officer and a director.  The 350,000 options issued during fiscal year ended May 31, 2013 have a ten year life with an exercise price of $1.05.  The options vested 50% upon issuance and the remainder will vest on May 22, 2014.  The 350,000 options were valued at $329,000.
	The Company’s principal offices are located at 133 Summit Avenue, Suite 22, Summit, New Jersey which are owned by Kirk M. Warshaw, LLC (the “LLC”), an affiliated company of Mr. Warshaw.  The Company occupies its principal offices on a month to month basis.  On March 1, 2010, it began paying a monthly fee of $500 to the LLC for the use and occupancy, and administrative services, related to its principal offices.

SENIOR_SECURED_CONVERTIBLE_NOT

SENIOR SECURED CONVERTIBLE NOTES - RELATED PARTY	6 Months Ended
	Nov. 30, 2013
Debt Disclosure [Abstract]	'
SENIOR SECURED CONVERTIBLE NOTES - RELATED PARTY	'
	NOTE 7. SENIOR SECURED CONVERTIBLE NOTES - RELATED PARTY
	On the Effective Date (defined in Note 2, above), the Company issued the $1 Million Secured Note to Niobe, its majority stockholder which is controlled by Arnold P. Kling, the Company’s president and director.  The $1 Million Secured Note bore interest at a rate of 3% per annum and had a scheduled maturity date of November 13, 2012.  The Company’s obligations under the $1 Million Secured Note were secured by a Security Agreement dated the Effective Date (the “Security Agreement”) which granted Niobe a security interest in substantially all of the Company’s personal property and assets, including its intellectual property.  On February 11, 2011, Niobe converted the $1 Million Secured Note, including $37,500 of accrued interest thereon, into 4,510,870 shares of Common Stock.
	On December 2, 2009, the Company entered into the Facility (defined in Note 2, above) with Niobe pursuant to which Niobe agreed to provide up to $2,000,000 of additional capital in the form of secured loans at any time prior to June 30, 2012 subject to the achievement of certain predetermined benchmarks.  In connection with the Facility, on December 2, 2009, the Security Agreement securing our obligations under the $1 Million Secured Note was amended and restated to also secure any incremental obligations under the Facility (the “Amended Security Agreement”).  Pursuant to the Amended Security Agreement, Niobe has a security interest in substantially all of our personal property and assets, including its intellectual property to collateralize all amounts due to it under the $1 Million Secured Note and the Facility.
	Pursuant to the Facility, on February 11, 2011, the Company received $2,000,000 of additional working capital from Niobe and issued the $2 Million Secured Note to Niobe.  The $2 Million Secured Note bore interest at a rate of 3% per annum and, as amended was scheduled to mature on December 31, 2013.  On August 27, 2013, Niobe elected to convert the $2 Million Secured Convertible Note and $155,000 of accrued interest thereunder into 9,369,565 shares of Common Stock.

SENIOR_SECURED_NOTES_RELATED_P

SENIOR SECURED NOTES - RELATED PARTY	6 Months Ended
	Nov. 30, 2013
Debt Disclosure [Abstract]	'
SENIOR SECURED NOTES - RELATED PARTY	'
	NOTE 8. SENIOR SECURED NOTES - RELATED PARTY
	On February 1, 2012, the Company raised $1,000,000 of working capital pursuant to a loan from Niobe.  The Company issued to Niobe a secured promissory note in the principal amount of $1,000,000 (the “February 2012 Secured Note”).  The February 2012 Secured Note bears interest at a rate of 3% per annum and matures on February 1, 2014.
	On June 5, 2012, the Company raised $1,000,000 of additional working capital pursuant to a loan from Niobe and issued to Niobe a secured promissory note in the principal amount of $1,000,000, which bears interest at a rate of 3% per annum and matures on May 31, 2014 (the “June 2012 Secured Note”).
	On October 1, 2012, the Company raised $800,000 of additional working capital pursuant to loans from Niobe and issued to Niobe secured promissory notes in the principal amount of $800,000, which bear interest at a rate of 3% per annum and matures on October 1, 2014 (the “October 2012 Secured Note”).
	On December 3, 2012, the Company raised $700,000 of additional working capital pursuant to a loan from Niobe and issued to Niobe a secured promissory note in the principal amount of $700,000, which bears interest at a rate of 3% per annum and matures on October 1, 2014 (the “December 2012 Secured Note”).
	Collectively, the February 2012 Secured Note, the June 2012 Secured Note, the October 2012 Secured Note and the December 2012 Secured Note are hereinafter referred to as the “2012 Secured Notes.”
	On January 18, 2013, the Company raised $2,500,000 of additional working capital pursuant to a loan from Niobe and issued to Niobe a secured promissory note in the principal amount of $2,500,000, which bears interest at a rate of 3% per annum and matures on January 15, 2015 (the “January 2013 Secured Note”).
	On May 13, 2013, the Company raised $2,000,000 of additional working capital pursuant to a loan from Niobe and issued to Niobe a secured promissory note in the principal amount of $2,000,000, which bears interest at a rate of 3% per annum and matures on May 13, 2015 (the “May 2013 Secured Note”).
	On August 27, 2013, the Company raised $1,000,000 of additional working capital pursuant to a loan from Niobe and issued to Niobe a secured promissory note in the principal amount of $1,000,000, which bears interest at a rate of 3% per annum and matures on August 27, 2015 (the “August 2013 Secured Note”).
	Collectively, the January 2013 Secured Note, the May 2013 Secured Note and the August 2013 Secured Note are hereinafter referred to as the “2013 Secured Notes.”
	Collectively, the 2012 Secured Notes and the 2013 Secured Notes represent a total of $9,000,000 in principal amount of loans from Niobe and are hereinafter referred to as the “Secured Notes.”
	On October 11, 2013, the Company issued a Consolidated, Amended and Restated Promissory Note to Niobe in the principal amount of $9,219,366.67 (the “Consolidated Note”).  The face amount of the Consolidated Note reflects the $9,000,000 aggregate principal amount of the Secured Notes plus interest accrued at 3% per annum on each note from its respective date of issuance.  The terms of the Consolidated Note are identical to the Secured Notes except that: (a) the maturity date is September 1, 2015, which is after the latest maturity date of any of the Secured Notes; and (b) it provides for partial mandatory repayment in the event that the Company receives aggregate gross proceeds in excess of $7,500,000 from a single or multiple “Liquidity Events” in an amount equal to twenty-five (25%) percent of such gross proceeds.  A “Liquidity Event” means (a) the sale of any of our equity, or equity-linked, securities, and (b) the receipt of proceeds, directly or indirectly related to a development and/or commercialization relationship entered into with an unaffiliated third party.  In the Secured Notes, the entire principal amount of each note was due, at Niobe’s election, upon the consummation of an equity financing of $7,500,000 or greater.  Consistent with the terms of the Secured Notes and related security agreements entered into, the Company’s obligations under the Consolidated Note are secured by a first priority perfected security interest in all of the assets of the Company pursuant to a Consolidated, Amended and Restated Security Agreement dated October 11, 2013 between the Company and Niobe.
	All of the securities issued in the aforementioned financings were issued in reliance upon the exemption from the registration requirements of the Securities Act of 1933, as amended (the “Act”) pursuant to Section 4(6) and Rule 506 of Regulation D thereof.  The offer, sale and issuance of such securities were made without general solicitation or advertising.  The securities were offered and issued only to “accredited investors” as such term is defined in Rule 501 under the Act.

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	6 Months Ended
	Nov. 30, 2013
Subsequent Events [Abstract]	'
SUBSEQUENT EVENTS	'
	NOTE 9. SUBSEQUENT EVENTS
	In December 2013 the Company issued non-qualified stock options for an aggregate of 700,000 shares of Common Stock, each with an exercise price of $8.50 per share, to four consultants. Each of the options expire 10 years from the date of grant.
	The foregoing options are subject to vesting and forfeiture and were issued in reliance upon the exemption from the registration requirement of the Act pursuant to Section 4(a)(2) of the Act.
	The Company has evaluated subsequent events and has determined that there were no other subsequent events to recognize or disclose in these financial statements.

BASIS_OF_PRESENTATION_AND_SUMM1

BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
	Nov. 30, 2013
Accounting Policies [Abstract]	'
Estimates	'
	Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions affecting the reported amounts of assets, liabilities, revenues and expense, and the disclosure of contingent assets and liabilities. Estimated amounts could differ materially from actual results.
Loss per Common Share	'
	Loss Per Common Share
	The Financial Accounting Standards Board (FASB) has issued guidance for “Earnings Per Share” which provides for the calculation of “Basic” and “Diluted” earnings per share. Basic earnings per share includes no dilution and is computed by dividing net loss to common stockholders by the weighted average number of common shares outstanding for the period. All potentially dilutive securities consisting of employee stock options and warrants have been excluded from the computations since they would be antidilutive. However, these dilutive securities could potentially dilute earnings per share in future periods. As of November 30, 2013 the Company had potentially dilutive securities consisting of 3,117,543 stock options.  As of November 30, 2012, the Company had potentially dilutive securities consisting of 2,642,191 stock options.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	For the purposes of reporting cash flows, the Company considers all cash accounts which are not subject to withdrawal restrictions or penalties, and highly liquid investments with original maturities of 60 days or less to be cash and cash equivalents. The cash and cash equivalent deposits are not insured by The Federal Deposit Insurance Corporation.
Share Based Compensation	'
	Share Based Compensation
	Effective June 1, 2006, the Company adopted the FASB accounting guidance for fair value recognition provisions of the “Accounting for Share-Based Payment” using the modified prospective method.  This standard requires the Company to measure the cost of employee services received in exchange for equity share options granted based on the grant-date fair value of the options.  The cost is recognized as compensation expense over the vesting period of the options.  Under the modified prospective method $728,571 and $342,312 compensation cost is included in operating expenses for the six months ended November 30, 2013 and November 30, 2012, respectively.  These amounts included both the compensation cost of stock options granted prior to but not yet vested as of June 1, 2006 and compensation cost for all options granted subsequent to May 31, 2006.  In accordance with the modified prospective application transition method, prior period results are not restated.  Incremental compensation cost for a modification of the terms or conditions of an award is measured by comparing the fair value of the modified award with the fair value of the award immediately before the modification.  No tax benefit was recorded as of November 30, 2013 in connection with these compensation costs due to the uncertainty regarding ultimate realization of certain net operating loss carryforwards.  The Company has also implemented the SEC interpretations in Staff Accounting Bulletin (“SAB”) for “Share-Based Payments,” in connection with the adoption of FASB accounting guidance.
	The Board of Directors adopted and the stockholders approved the 2003 Stock Option Plan in October 2003 which was subsequently amended in October 2005. The plan was adopted to recognize the contributions made by the Company’s employees, officers, consultants, and directors, to provide those individuals with additional incentive to devote themselves to the Company’s future success, and to improve the Company’s ability to attract, retain and motivate individuals upon whom the Company’s growth and financial success depends. Under the plan, stock options for up to 900,000 shares may be granted as approved by the Board of Directors or the Compensation Committee.  No options granted under the plan are exercisable after the expiration of ten years (or less in the discretion of the Board of Directors or the Compensation Committee) from the date of the grant. The plan will continue in effect until terminated or amended by the Board of Directors.
	The accounting guidance requires the use of a valuation model to calculate the fair value of each stock-based award. The Company uses the Black-Scholes model to estimate the fair value of stock options granted based on the following assumptions:
	Expected Term or Life. The expected term or life of stock options granted issued represents the expected weighted average period of time from the date of grant to the estimated date that the stock option would be fully exercised. The weighted average expected option term was determined using a combination of the “simplified method” for plain vanilla options as allowed by the accounting guidance. The “simplified method” calculates the expected term as the average of the vesting term and original contractual term of the options.
	Expected Volatility. Expected volatility is a measure of the amount by which the Company’s stock price is expected to fluctuate. Expected volatility is based on the historical daily volatility of the price of our common shares. The Company estimated the expected volatility of the stock options at grant date.
	Risk-Free Interest Rate. The risk-free interest rate is based on the implied yield on U.S. Treasury zero-coupon issues with remaining terms equivalent to the expected term of our stock-based awards.
	As of November 30, 2013, there were 3,117,543 stock options outstanding of which an aggregate of 37,000 were options granted under the plan and 3,080,543 were non-plan option grants.  At November 30, 2013, the aggregate unrecognized compensation cost of unvested options, as determined using a Black-Scholes option valuation model, was approximately $376,750 (net of estimated forfeitures) which will be recognized ratably through May 2014.  The remaining amount of options will be valued once they vest upon the future events.  During the six months ended November 30, 2013, the Company granted 100,000 stock options and 40,000 options expired.
	The fair value of the options is estimated on the date of the grant using the Black-Scholes option pricing model with the following assumptions:
		Six Months Ended			Six Months Ended			From Inception
		November 30, 2013			November 30, 2012			Through
								November 30, 2013
	Dividends per year		0			0			0
	Volatility percentage		418% - 426	%		97.5	%		90%-426	%
	Risk free interest rate		2.13	%		3.47	%		1.74%-5.11	%
	Expected life (years)		7.0-10.0			7.0-10.0			10-Mar
	Weighted Average Fair Value	$	1.24		$	1.07		$	2.3

BASIS_OF_PRESENTATION_AND_SUMM2

BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	6 Months Ended
	Nov. 30, 2013
Accounting Policies [Abstract]	'
Fair Value of Assumptions of Options Estimated On Grant Date	'
	The fair value of the options is estimated on the date of the grant using the Black-Scholes option pricing model with the following assumptions:
		Six Months Ended			Six Months Ended			From Inception
		November 30, 2013			November 30, 2012			Through
								November 30, 2013
	Dividends per year		0			0			0
	Volatility percentage		418% - 426	%		97.5	%		90%-426	%
	Risk free interest rate		2.13	%		3.47	%		1.74%-5.11	%
	Expected life (years)		7.0-10.0			7.0-10.0			10-Mar
	Weighted Average Fair Value	$	1.24		$	1.07		$	2.3

ORGANIZATION_AND_BUSINESS_ACTI1

ORGANIZATION AND BUSINESS ACTIVITIES - Additional Information (Detail) (USD $)	Nov. 30, 2013	31-May-13	Dec. 08, 2010
Organization and Nature Of Operations [Line Items]	'	'	'
Reverse stock split, Common stock, par value	$0.00	$0.00	$0.00

CHANGE_OF_OWNERSHIP_TRANSACTIO1

CHANGE OF OWNERSHIP TRANSACTION - Additional Information (Detail) (USD $)

6 Months Ended

9 Months Ended

12 Months Ended

1 Months Ended

1 Months Ended

1 Months Ended

Nov. 30, 2013

31-May-00

31-May-11

31-May-10

31-May-02

31-May-01

Oct. 11, 2013

Oct. 11, 2013

Aug. 27, 2013

13-May-13

Jan. 18, 2013

Dec. 03, 2012

Oct. 01, 2012

Jun. 05, 2012

Feb. 01, 2012

Aug. 31, 2013

Nov. 11, 2009

Feb. 11, 2011

Nov. 11, 2009

Feb. 11, 2011

Senior Secured Note

Niobe Ventures LLC

Niobe Ventures LLC

Niobe Ventures LLC

Niobe Ventures LLC

Niobe Ventures LLC

Niobe Ventures LLC

Niobe Ventures LLC

Niobe Ventures LLC

Niobe Ventures LLC

Niobe Ventures LLC

Niobe Ventures LLC

Credit Facility Agreement

Senior Secured Note

Senior Secured Note

Senior Secured Note

Senior Secured Note

Senior Secured Note

Senior Secured Note

Senior Secured Note

Senior Secured Note

Securities Purchase Agreement

Securities Purchase Agreement

Securities Purchase Agreement

Niobe Ventures LLC

Senior Secured Note

Senior Secured Note

Senior Secured Note

Class of Stock [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Additional working capital raised

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$3,000,000

'

'

'

Restricted shares of common stock issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8,695,652

'

'

'

Common Stock issued, per share

'

$0.15

'

$0.23

$6.25

$5

'

'

'

'

'

'

'

'

'

'

$0.23

'

'

'

Restricted shares of common stock issued, value

2,155,000

'

1,037,500

2,000,000

1,102,000

425,000

'

'

'

'

'

'

'

'

'

'

2,000,000

'

'

'

Senior secured convertible promissory note

'

'

'

'

'

'

'

'

2,000,000

'

'

'

'

'

'

'

'

1,000,000

1,000,000

2,000,000

Accrued interest on senior secured convertible promissory note

'

'

'

'

'

'

'

'

155,000

'

'

'

'

'

'

'

'

37,500

'

'

Senior secured convertible promissory note, conversion price per share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.23

$0.23

Shares of common stock issuable upon conversion of senior secured convertible promissory note

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,510,870

'

'

Senior secured convertible promissory note, maturity date

'

'

'

'

'

'

'

1-Sep-15

27-Aug-15

13-May-15

15-Jan-15

1-Oct-14

1-Oct-14

31-May-14

1-Feb-14

'

'

'

'

31-Dec-12

Senior secured convertible promissory note, extended maturity date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

31-Dec-13

Debt instrument, interest rate, effective percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3.00%

Proceeds from secured notes payable

'

'

'

'

'

'

'

'

1,000,000

2,000,000

2,500,000

700,000

800,000

1,000,000

1,000,000

'

'

'

'

'

Debt instrument, face amount

'

'

'

'

'

'

9,000,000

9,000,000

1,000,000

2,000,000

2,500,000

700,000

800,000

1,000,000

1,000,000

9,000,000

'

'

'

'

Secured note payable, interest rate

'

'

'

'

'

'

'

3.00%

3.00%

3.00%

3.00%

3.00%

3.00%

3.00%

3.00%

'

'

'

'

'

Debt Conversion, Converted Instrument, Shares Issued

'

'

'

'

'

'

'

'

9,369,565

'

'

'

'

'

'

'

'

'

'

'

Debt instrument carrying amount

'

'

'

'

'

'

'

9,219,366.67

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Repayments of secured debt

'

'

'

'

'

'

'

7,500,000

'

'

'

'

'

'

'

'

'

'

'

'

Terms of consolidated note identical to secured notes

'

'

'

'

'

'

'

'(a) the maturity date is September 1, 2015, which is after the latest maturity date of any of the Secured Notes; and (b) it provides for partial mandatory repayment in the event that the Company receives aggregate gross proceeds in excess of $7,500,000 from a single or multiple Liquidity Events in an amount equal to twenty-five (25%) percent of such gross proceeds.

'

'

'

'

'

'

'

'

'

'

'

'

Description of Liquidity Event

'

'

'

'

'

'

'

'(a) the sale of any of our equity, or equity-linked, securities, and (b) the receipt of proceeds, directly or indirectly related to a development and/or commercialization relationship entered into with an unaffiliated third party

'

'

'

'

'

'

'

'

'

'

'

'

Consummation of equity financing, amount

'

'

'

'

'

'

'

$7,500,000

'

'

'

'

'

'

'

'

'

'

'

'

GOING_CONCERN_Additional_Infor

GOING CONCERN - Additional Information (Detail) (USD $)

3 Months Ended

6 Months Ended

9 Months Ended

12 Months Ended

170 Months Ended

Nov. 30, 2013

Nov. 30, 2012

Nov. 30, 2013

Nov. 30, 2012

31-May-00

31-May-13

31-May-12

31-May-11

31-May-10

31-May-09

31-May-08

31-May-07

31-May-06

31-May-05

31-May-04

31-May-03

31-May-02

31-May-01

Nov. 30, 2013

Sep. 16, 1999

Cash Flow Supplemental Disclosures [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deficit accumulated during the development stage

$64,738,846

'

$64,738,846

'

'

$61,735,053

'

'

'

'

'

'

'

'

'

'

'

'

$64,738,846

'

Net loss

1,491,550

1,420,963

3,003,793

2,784,998

250,689

6,280,234

4,444,584

3,357,882

3,067,842

7,230,206

10,490,758

8,451,942

6,104,402

5,567,729

2,989,364

1,665,090

1,280,465

553,866

64,738,846

'

Cash used in operating activities

'

'

-2,373,106

-1,957,984

'

4,733,349

2,351,630

'

'

'

'

'

'

'

'

'

'

'

-52,266,694

'

Cash and cash equivalents

1,083,940

32,411

1,083,940

32,411

'

2,457,046

190,395

'

'

'

'

'

'

'

'

'

'

'

1,083,940

0

Net working capital deficit

$634,730

'

$634,730

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$634,730

'

BASIS_OF_PRESENTATION_AND_SUMM3

BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Detail) (USD $)	6 Months Ended
	Nov. 30, 2013	Nov. 30, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Aggregate unrecognized compensation cost of unvested options	$376,750	'
Share based compensation, number of stock options expired during period	40,000	'
Share-based compensation arrangement by share-based payment award, options, grants in period, gross	100,000	'
Plan Option Grants	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share based compensation, number of stock options outstanding	37,000	'
Non Plan Option Grants	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share based compensation, number of stock options outstanding	3,080,543	'
Stock Incentive Plan 2003	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Number of shares reserved for grants of options	900,000	'
Stock option exercisable expiration period	'10 years	'
Operating Expense	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Compensation cost included in operating expenses	$728,571	$342,312
Stock Option	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Potentially dilutive securities	3,117,543	2,642,191

Fair_Value_of_Assumptions_of_O

Fair Value of Assumptions of Options Estimated on Grant Date (Detail) (USD $)	6 Months Ended		170 Months Ended
	Nov. 30, 2013	Nov. 30, 2012	Nov. 30, 2013
Assumptions used to Determine Fair Value Options [Line Items]	'	'	'
Dividends per year	$0	$0	$0
Volatility percentage	'	97.50%	'
Risk free interest rate	2.13%	3.47%	'
Weighted Average Fair Value	$1.24	$1.07	$2.30
Minimum	'	'	'
Assumptions used to Determine Fair Value Options [Line Items]	'	'	'
Volatility percentage	418.00%	'	90.00%
Risk free interest rate	'	'	1.74%
Expected life (years)	'7 years	'7 years	'3 years
Maximum	'	'	'
Assumptions used to Determine Fair Value Options [Line Items]	'	'	'
Volatility percentage	426.00%	'	426.00%
Risk free interest rate	'	'	5.11%
Expected life (years)	'10 years	'10 years	'10 years

RELATED_PARTIES_Additional_Inf

RELATED PARTIES - Additional Information (Detail) (USD $)	6 Months Ended	1 Months Ended	12 Months Ended
	Nov. 30, 2013	Mar. 01, 2010	31-May-13
		Monthly Payment	Mr. Warshaw
Related Party Transaction [Line Items]	'	'	'
Payment for the use and occupancy, and administrative services, related to principal offices	'	$500	'
Share-based compensation arrangement by share-based payment award, options, grants in period, gross	100,000	'	350,000
Share-based compensation arrangement by share-based payment award, award vesting period	'	'	'10 years
Weighted average exercise price of options	'	'	$1.05
Share-based compensation arrangement by share-based payment award, award vesting rights	'	'	'The options vested 50% upon issuance and the remainder will vest on May 22, 2014.
Fair value of options	'	'	$329,000

SENIOR_SECURED_CONVERTIBLE_NOT1

SENIOR SECURED CONVERTIBLE NOTES - RELATED PARTY - Additional Information (Detail) (USD $)	Oct. 11, 2013	Feb. 11, 2011	Dec. 02, 2009	Aug. 27, 2013	Feb. 11, 2011	Nov. 11, 2009	Dec. 02, 2009
				Niobe Ventures, LLC	Niobe Ventures, LLC	Niobe Ventures, LLC	Niobe Ventures, LLC
				Senior Secured Convertible Notes	Senior Secured Convertible Notes	Senior Secured Convertible Notes	Senior Secured Convertible Notes
Debt Instrument [Line Items]	'	'	'	'	'	'	'
Secured note payable, additional borrowing amount	'	$2,000,000	'	'	'	'	$2,000,000
Debt instrument, face amount	9,000,000	'	'	'	2,000,000	1,000,000	'
Debt instrument, interest rate during Period	'	'	'	'	3.00%	3.00%	'
Secured note payable, maturity date	'	'	'	'	31-Dec-13	13-Nov-12	'
Debt conversion, converted instrument, shares issued	'	'	'	9,369,565	4,510,870	'	'
Convertible debt, current	'	'	1,000,000	'	1,000,000	'	'
Accrued interest on senior secured convertible promissory note	'	'	'	155,000	37,500	'	'
Debt Conversion, Converted Instrument, Amount	'	'	'	$2,000,000	'	'	'

SENIOR_SECURED_NOTES_RELATED_P1

SENIOR SECURED NOTES - RELATED PARTY - Additional Information (Detail) (USD $)	Oct. 11, 2013	Oct. 11, 2013	Oct. 11, 2013	Aug. 27, 2013	13-May-13	Jan. 18, 2013	Dec. 03, 2012	Oct. 01, 2012	Jun. 05, 2012	Feb. 01, 2012	Aug. 31, 2013
		Senior Secured Notes	Senior Secured Notes	Niobe Ventures, LLC	Niobe Ventures, LLC	Niobe Ventures, LLC	Niobe Ventures, LLC	Niobe Ventures, LLC	Niobe Ventures, LLC	Niobe Ventures, LLC	Niobe Ventures, LLC
			Minimum	Senior Secured Notes	Senior Secured Notes	Senior Secured Notes	Senior Secured Notes	Senior Secured Notes	Senior Secured Notes	Senior Secured Notes	Senior Secured Notes
Debt Instrument [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Proceeds from issuance of secured note	'	'	'	$1,000,000	$2,000,000	$2,500,000	$700,000	$800,000	$1,000,000	$1,000,000	'
Secured note payable	9,000,000	'	'	1,000,000	2,000,000	2,500,000	700,000	800,000	1,000,000	1,000,000	9,000,000
Secured note payable, interest rate	'	3.00%	'	3.00%	3.00%	3.00%	3.00%	3.00%	3.00%	3.00%	'
Secured note payable, maturity date	'	1-Sep-15	'	27-Aug-15	13-May-15	15-Jan-15	1-Oct-14	1-Oct-14	31-May-14	1-Feb-14	'
Debt instrument carrying amount	'	9,219,366.67	'	'	'	'	'	'	'	'	'
Proceeds from Repayments of secured debt	'	7,500,000	'	'	'	'	'	'	'	'	'
Terms of consolidated note identical to secured notes	'	'(a) the maturity date is September 1, 2015, which is after the latest maturity date of any of the Secured Notes; and (b) it provides for partial mandatory repayment in the event that the Company receives aggregate gross proceeds in excess of $7,500,000 from a single or multiple Liquidity Events in an amount equal to twenty-five (25%) percent of such gross proceeds.	'	'	'	'	'	'	'	'	'
Description of liquidity event	'	'(a) the sale of any of our equity, or equity-linked, securities, and (b) the receipt of proceeds, directly or indirectly related to a development and/or commercialization relationship entered into with an unaffiliated third party.	'	'	'	'	'	'	'	'	'
Consummation of equity financing, amount	'	'	$7,500,000	'	'	'	'	'	'	'	'

SUBSEQUENT_EVENTS_Additional_I

SUBSEQUENT EVENTS - Additional Information (Detail) (Subsequent Event, Non Qualified Stock Option, USD $)	1 Months Ended
	Dec. 31, 2013
Subsequent Event | Non Qualified Stock Option	'
Subsequent Event [Line Items]	'
Stock issued during period, shares, new issues	700,000
Share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price	$8.50
Expiry term of options	'10 years